Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults

We performed a double-blind, randomized, controlled phase I study to assess safety, immunogenicity, and antibody persistence of the new meningococcal group A conjugate vaccine (PsA-TT) in healthy volunteers aged 18-35 years. Of the 74 male subjects enrolled, 24 received the PsA-TT vaccine (Group 1), 25 received the Meningoccoccal Polysaccharide Vaccine A+C(TM) Pasteur, Lyon, France (Group 2), and 25 received the Tetanus Toxoid Vaccine Adsorbed(TM), SIIL, Pune India (Group 3). No immediate reactions were observed. Local and systemic solicited reactions within 7 days post-vaccination and unsolicited adverse events (AEs) were mild and similar among the three groups and resolved without sequelae. No serious AEs were notified up to I year post-vaccination. Four weeks post-vaccination, a slightly higher proportion of Group I subjects had a four-fold increase in SBA titers compared to Group 2 subjects (83% versus 72%, p > 0.05). SBA GMTs in Groups 2 and 3 were higher than in Group 3 (p < 0.05). Serogroup A-specific IgG GMCs were significantly higher in Group I than in Groups 2 (p < 0.05) and 3 (p < 0.05). After I year SBA titers were significantly higher in Group I than in Group 2 (p < 0.05). The new PsA-TT vaccine was shown to be safe. immunogenic, and able to elicit persistent functional antibody titers in adults. This opens the prospective for further development and licensure of this vaccine to eliminate epidemic meningitis in sub-Saharan Africa. (C) 2007 Elsevier Ltd. All rights reserved.